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At the end of the 1950s and the beginning of the 1960s,
many desperate cluster headache (CH) patients came to
the Headache Center of Florence, the only one in Europe
at the time, to be examined. I was there… 
Horton’s headache era
More than 60 years ago Graham and Wolff [1, 2] pro-
posed the vascular theory of migraine and related vascu-
lar headaches. At that time the clinical feature of the cur-
rent CH syndrome was considered a migraine variant and
therefore headache phase was attributed to painful
dilatation and distension of the cephalic blood vessels. In
1939 Horton et al. [3] described cluster attack features,
including increased temperature of the symptomatic side
of the forehead and he reported the experience in treat-
ing this new vascular headache syndrome with hista-
mine. But only in 1956, when Horton detailed the pain
and its associated symptoms, did the syndrome become
generally known [4]. However, Horton focused on the
symptoms of episodes, omitting a description of the peri-
odicity of occurrences. Therefore he considered this syn-
drome a vascular headache with chronic recurrent brief
attacks similar to migraine. Horton used the term “hista-
minic cephalgia” [5] or “cephalalgia” [6], as he attrib-
uted this vascular painful syndrome to the potent
vasodilator agent histamine. In many circles this form of
headache has been called Horton’s headache in his hon-
our. Apart from acetylcholine, at that time histamine was
the only known vasodilatative substance capable of
explaining the vasodilatation phase of the so-called vas-
cular headaches. Horton focused on the presumed role of
histamine as an inducing factor of CH attacks as well as
their prevention with histaminic desensitisation, and had
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also observed that histamine subcutaneously provoked a
cutaneous rash with increased temperature. Moreover,
peptic ulcer was found to be a common affliction of
these male patients and during the attacks gastric acid
secretion increased. Although the pathogenetic implica-
tion of this term seems today rather small for progress in
the field, Horton’s definition raised our comprehension
of this headache to a level able to promote a lot of enthu-
siastic research and well designed diagnostic and thera-
peutic procedures.
The disorder was attributed by Horton to a unique
form of histamine sensitivity. The evidence for this was
cited as follows “…a headache apparently identical with
that of a spontaneous attack could be precipitated in some
patients by the hypodermic administration of histamine in
a small amounts, usually 0.35 mg histamine base. Gastric
acidity was found to rise during an attack and attack sub-
side after histamine desensitisation over an extended peri-
od of time” [4].
The pathophysiological role of vasoactive substances
such as kinins and serotonin would be studied some
years later.
Horton’s headache era at the Headache Center of
Florence
According to the accurate description of Horton’s patient
series, there was a veritable explosion of interest regard-
ing this type of headache in the world headache commu-
nity. In 1964 Greppi and Sicuteri presented at the
National Congress of Internal Medicine Society in Rome
a lecture entitled “Migraine: aspects of physiopathogen-
esis and therapy” with an appendix by Franchi and
Fanciullacci in which they reported 71 cases of hista-
minic cephalalgia [7]. But how were the patients man-
aged at that time? I remember many of these patients
were examined every day during their hospitalisation.
Every day courage was required to say “I do not know”
and to show greater commitment to try to help these
patients. Every day it was necessary to explain to our
colleagues not involved in headache how to manage the
uncontrolled manifestations sometimes shown by these
patients, and explain the intensity of their sufferings to
avoid a psychiatric interpretation of their behaviour dur-
ing the attack.
The most important factor in therapy was the assur-
ance that a dedicated and understanding physician
would stick with each patient over the year through the
trials and tribulations of this miserable malady. More
than 20 years ago a chronic cluster patient described his
terrible painful experience in a book named “Horton”,
dedicated to all of Horton’s patients, which is composed
of a series of dramatic poems on his suffering. He gave
me the book as a gift, with this dedication “With great
estimation and gratitude. The care of a dedicated doctor,
with experience of this terrible disease, like myself,
became of great value for the patient, despite the poor
therapeutic possibility represented by the empiric hista-
mine desensitisation, ergotamine compound and methy-
sergide. In fact, the patient’s suffering put special
demands on the treating physician concerning his empa-
thy and understanding of the patient’s whole situation.
Histamine desensitisation has been used for many years
for the treatment of patients affected by Horton’s
headache. This therapy usually entails a prolonged hos-
pital stay during which the interrelation between doctor
and patient is very strong. I remember our technique of
“protected” histamine desensitisation for slow infusion
of histamine bichloride or the histamine releaser com-
pound 48/80, gradually increasing the dose up to 5–6
mg/day. The protection was carried out with preventive
or simultaneous administration of antihistaminic drugs
and sometimes with dihydroergotamine in the same
phleboclysis to prevent the induction of a crisis. The
scenario was that of a patient engaged in following the
speed of infusion in order to avoid the trigger of an
attack and the doctor’s intervention to block the possi-
ble attack with parenteral dihydroergotamine. The hos-
pitalised patient illustrates how the histamine adminis-
tration in desensitising amount effected by a physician
in whom he had complete confidence and reassurance,
when compared with the past chaotic management, may
have had same effect in alleviating his headache for
some time.
Cluster headache. The first direct approach to pupillary
neural innervation
The term proposed in the 1950s by Kunkle et al., i.e.,
cluster headache [8], has been widely accepted, in Italy
as well, and our Horton’s patients had their name
changed to CH patients. With youthful enthusiasm, my
colleagues and I achieved a craftsmanlike photographic
technique with the aim of directly exploring the neural
structures of the pupil, which are unilaterally affected
during the attack. With a battery of sympathetically act-
ing eye drops, the pupillary impairment of sympathetic
neuronal activity was demonstrated. Tyramine eye
drops in CH patients induced an anisocoric pattern
characterised by the pupil on the symptomatic side
being smaller than the other pupil [9, 10]. Asymmetric
mydriatic response to the noradrenaline releaser tyra-
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mine was proposed as an objective diagnostic test for
cluster patients. Also, it was pointed out that chronic
lithium treatment corrects the asymmetric response to
tyramine in CH patients [11]. We considered that this
peripheral adrenergic disorder could reflect an analogue
disturbance in the central nervous system and therefore
it may be applicable to Sicuteri’s central theory, which
considers primary headaches to be due to a brain defi-
ciency of a monoamine, particularly serotonin [12].
Some years later our group also showed a dysfunction
in the trigeminal iris innervation on the symptomatic
side [13].
In one of the first Italian books about primary
headaches, Nappi and Savoldi presented hypothalamic-
limbic injury involving both dysfunction of central
oscillators and dysfunction of central lateral organisa-
tion with lateral asymmetry increase in neurotransmitter
systems [14]. These were Italian researchers’ intuitions
of a central origin of the pupillary dysfunction that was
considered peripheral in origin by the majority of world
headache researchers. In fact it was supposed that the
inflammatory process, present during CH periods in the
walls of the cavernous sinus, caused a lesion of the
adjacent sympathetic fibres and possibly also pain
fibres [15].
My first time with sumatriptan
In the past, CH attacks were the most difficult to treat.
Parenteral administration of ergotamine compounds rep-
resented the most effective symptomatic therapy. Horton
first demonstrated the termination of an attack with par-
enteral ergotamine tartrate (0.30 mg).
Dihydroergotamine has a more favourable tolerability
profile than ergotamine and it was used extensively in its
parenteral form (1 mg). Because of their long duration of
action, they were used also to prevent the attack if the
headache was recurring at a predictable time. However
their action was very slow and a pain-free effect has
rarely been obtained. In the late 1980s in a pilot study the
first results concerning subcutaneous sumatriptan in CH
acute treatment were obtained. These results prompted
further placebo-controlled studies to determine the effi-
cacy, safety and tolerability of sumatriptan in CH. I had
the opportunity to participate in the first randomised,
double-blind, placebo-controlled crossover study [16].
Two minutes after active drug injection the patient said
“my crisis is disappearing…”. After the first moment of
incredulity, I felt great emotion and satisfaction: it was
evident that sumatriptan would improve the quality of life
in patients with CH attacks, as the optimal treatment for
rapid resolution of attacks, which are commonly very
severe, was emerging. Moreover, the effect of sumatrip-
tan, a 5HT receptor agonist, seemed to agree with our
results obtained a long time before, which indicated the
therapeutic drugs ergotamine and methysergide as sero-
tonin agents [17].
The past, the present and the future
My “amarcord” is not sad but full of enthusiastic per-
spectives. My colleagues and I, interested not only in the
diagnosis and treatment of headaches but also in
research, had a great opportunity to participate in pio-
neering frontline research and clinical practice into CH.
In the mid 1960s only three or four papers on CH
appeared every year. During the 1970s some investiga-
tors became interested in this topic and, in order to pro-
mote research ideas, a group was set up by Ottar
Sjaastad. It was called the “International Cluster
Headache Research Group”, but for practical reasons
this name was abbreviated to the “Cluster Club” [18]. I
had the opportunity to be a member of the club, repre-
senting the Florence Headache Center, accepting the
challenge to consider the vascular component of CH as a
secondary factor. At that time, the majority of headache
experts considered that the speculation concerning the
possibility of the central nervous system being an essen-
tial factor in CH did not fit the facts. Past research has
contributed to stimulate the current research, which has
confirmed the central basic neural cause of CH. Recent
decades in fact have brought a considerable increase in
clinical and experimental research suggesting a role for
hypothalamus in the disorder. Consequently, the vascular
theory has been superseded by recognition that neu-
rovascular factors are more important. Neuroimaging has
broadened this pathophysiological view and has led to
successful treatment by deep brain stimulation of the
hypothalamus [19]. Bearing in mind the excruciating
pain in CH, we must now accept the challenge of avoid-
ing diagnostic delay and the mismanagement of CH,
which still occurs [20]. My regret is the fact that many
patients are not optimally managed in their early disease
course. Possibly, this could avoid more invasive proce-
dures. Every effort must be made to minimise the
patient’s disability and suffering. The challenge is to
establish a clinical background capable of giving the
optimal modern management to CH patients, similar to
patients with other seriously disabling diseases. It is rea-
sonable to believe that in the near future better education
and new treatments will reach this target and I hope to
say again “I was there…”.
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